Nesfatin-1; implication in stress and stress-associated anxiety and depression

Current Pharmaceutical Design

Volumn 19, Issue 39, 2013, Pages 6941-6948

  Emmerzaal, T L ^a   Kozicz, T ^a,b  

^a RADBOUD UNIVERSITY   (Netherlands)

^b TULANE UNIVERSITY   (United States)

Author keywords

Acute stress; Chronic stress; Energy metabolism; Human; Nucleobindin 2; Psychopathology; Rodent

Indexed keywords

ANOREXIGENIC AGENT; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CORTICOTROPIN RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR; MELANIN CONCENTRATING HORMONE; NESFATIN 1; NEUROPEPTIDE; NEUROTENSIN; NUCLEOBINDIN 2; OXYTOCIN; PROOPIOMELANOCORTIN; PROTEIN PRECURSOR; PROTIRELIN; SEROTONIN; SOMATOSTATIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; UROCORTIN I; VASOPRESSIN;

ACUTE STRESS; ANXIETY DISORDER; ARTICLE; BRAIN NERVE CELL; CHRONIC STRESS; DEPRESSION; FUNCTIONAL ANATOMY; HUMAN; HYPOTHALAMUS; IMMUNOREACTIVITY; MENTAL STRESS; NEUROANATOMY; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SEX DIFFERENCE;

ANIMALS; ANXIETY; CALCIUM-BINDING PROTEINS; DEPRESSION; DNA-BINDING PROTEINS; HUMANS; NERVE TISSUE PROTEINS; STRESS, PSYCHOLOGICAL;

EID: 84885859066     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161281939131127125042     Document Type: Article

References (86)

1. Oh S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443(7112): 709-12.
2. Cunningham JJ, Calles-Escandon J, Garrido F, Carr DB, Bode HH. Hypercorticosteronuria and diminished pituitary responsiveness to corticotropin-releasing factor in obese Zucker rats. Endocrinology 1986; 118(1): 98-101.
3. Dallman MF, Pecoraro NC, La Fleur SE, et al. Glucocorticoids, chronic stress, and obesity. Progress Brain Res 2006; 153: 75-105.
4. Harris RBS, Mitchell TD, Simpson J, et al. Weight loss in rats exposed to repeated acute restraint stress is independent of energy or leptin status. Am J Physiol-Regulatory, Integrative Comparative Physiol 2002; 282(1): R77-R88.
5. Zelena D, Földes A, Mergl Z, et al. Effects of repeated restraint stress on hypothalamo-pituitary-adrenocortical function in vasopressin deficient Brattleboro rats. Brain Res Bulletin 2004; 63(6): 521-30.
6. Joëls M, Baram TZ. The neuro-symphony of stress. Nature Rev Neurosci 2009; 10(6): 459-66.
7. Koob GF, Heinrichs SC. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 1999; 848(1): 141-52.
8. Cook CJ. Stress induces CRF release in the paraventricular nucleus, and both CRF and GABA release in the amygdala. Physiol Behav 2004; 82(4): 751-62.
9. Gysling K, Forray MI, Haeger P, Daza C, Rojas R. Corticotropinreleasing hormone and urocortin: redundant or distinctive functions? Brain Res Rev 2004; 47(1): 116-25.
10. De Kloet ER, Joëls M, Holsboer F. Stress and the brain: from adaptation to disease. Nature Rev Neurosci 2005; 6(6): 463-75.
11. Kozicz T. On the role of urocortin 1 in the non-preganglionic Edinger-Westphal nucleus in stress adaptation. General Comparative Endocrinol 2007; 153(1): 235-40.
12. Koylu EO, Balkan B, Kuhar MJ, Pogun S. Cocaine and amphetamine regulated transcript (CART) and the stress response. Peptides 2006; 27(8): 1956-69.
13. Stanek LM. Cocaine-and amphetamine related transcript (CART) and anxiety. Peptides 2006; 27(8): 2005-11.
14. Rogge G, Jones D, Hubert G, Lin Y, Kuhar M. CART peptides: regulators of body weight, reward and other functions. Nature Rev Neurosci 2008; 9(10): 747-58.
15. Weninger SC, Dunn AJ, Muglia LJ, et al. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Natl Acad Sci 1999; 96(14): 8283-8.
16. Weninger SC, Peters LL, Majzoub JA. Urocortin expression in the Edinger-Westphal nucleus is up-regulated by stress and corticotropin-releasing hormone deficiency. Endocrinology 2000; 141(1): 256-63.
17. Kozicz T, Li M, Arimura A. The activation of urocortin immunoreactive neurons in the Edinger-Westphal nucleus following acute pain stress in rats. Stress: The Int J Biol Stress 2001; 4(2): 85-90.
18. Gaszner B, Csernus V, Kozicz T. Urocortinergic neurons respond in a differentiated manner to various acute stressors in the Edinger-Westphal nucleus in the rat. J Comparative Neurol 2004; 480(2): 170-9.
19. Korosi A, Schotanus S, Olivier B, Roubos EW, Kozicz T. Chronic ether stress-induced response of urocortin 1 neurons in the Edinger-Westphal nucleus in the mouse. Brain Res 2005; 1046(1): 172-9.
20. Thorsell A. Brain neuropeptide Y and corticotropin-releasing hormone in mediating stress and anxiety. Experimental Biol Med 2010; 235(10): 1163-7.
21. Heilig M, Koob GF, Ekman R, Britton KT. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci 1994; 17(2): 80-5.
22. Maniam J, Morris MJ. The link between stress and feeding behaviour. Neuropharmacology 2012; 63(1): 97-110.
23. Daugé V, Léna I. CCK in anxiety and cognitive processes. Neurosci Biobehavioral Rev 1998; 22(6): 815-25.
24. Siegel R, Düker EM, Pahnke U, Wuttke W. Stress-induced changes in cholecystokinin and substance P concentrations in discrete regions of the rat hypothalamus. Neuroendocrinology 1987; 46(1): 75-81.
25. Becker C, Zeau B, Rivat C, et al. Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin. Molecular Psychiatry 2007; 13(12): 1079-92.
26. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994; 15(4): 731-55.
27. Onaka T, Takayanagi Y, Yoshida M. Roles of Oxytocin Neurones in the Control of Stress, Energy Metabolism, and Social Behaviour. J Neuroendocrinol 2012; 24(4): 587-98.
28. Goebel-Stengel M, Wang L, Stengel A, Taché Y. Localization of nesfatin-1 neurons in the mouse brain and functional implication. Brain Res 2011; 1396: 20-34.
29. Fort P, Salvert D, Hanriot L, et al. The satiety molecule nesfatin-1 is co-expressed with melanin concentrating hormone in tuberal hypothalamic neurons of the rat. Neuroscience 2008; 155(1): 174-81.
30. Foo K, Brismar H, Broberger C. Distribution and neuropeptide coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience 2008; 156(3): 563-79.
31. Brailoiu GC, Dun SL, Brailoiu E, et al. Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 2007; 148(10): 5088-94.
32. Goebel M, Stengel A, Wang L, Lambrecht NWG, Taché Y. Nesfatin-1 immunoreactivity in rat brain and spinal cord autonomic nuclei. Neurosci letters 2009; 452(3): 241-6.
33. Stengel A, Goebel M, Wang L, et al. Central nesfatin-1 reduces dark-phase food intake and gastric emptying in rats: differential role of corticotropin-releasing factor2 receptor. Endocrinology 2009; 150(11): 4911-9.
34. Xu L, Bloem B, Gaszner B, Roubos E, Kozicz T. Sex-specific effects of fasting on urocortin 1, cocaine-and amphetamineregulated transcript peptide and nesfatin-1 expression in the rat Edinger-Westphal nucleus. Neuroscience 2009; 162(4): 1141-9.
35. Okere B, Xu L, Roubos EW, Sonetti D, Kozicz T. Restraint stress alters the secretory activity of neurons co-expressing urocortin-1, cocaine-and amphetamine-regulated transcript peptide and nesfatin-1 in the mouse Edinger-Westphal nucleus. Brain Res 2010; 1317: 92-9.
36. Kohno D, Nakata M, Maejima Y, et al. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 2008; 149(3): 1295-301.
37. Bonnet MS, Pecchi E, Trouslard J, et al. Central nesfatin-1-expressing neurons are sensitive to peripheral inflammatory stimulus. J Neuroinflammation 2009; 6(1): 27-35.
38. Könczöl K, Bodnár I, Zelena D, et al. Nesfatin-1/NUCB2 may participate in the activation of the hypothalamic-pituitary-adrenal axis in rats. Neurochem Int 2010; 57(3): 189-97.
39. Xu L, Bloem B, Gaszner B, Roubos E, Kozicz T. Stress-related changes in the activity of cocaine-and amphetamine-regulated transcript and nesfatin neurons in the midbrain non-preganglionic Edinger-Westphal nucleus in the rat. Neuroscience 2010; 170(2): 478-88.
40. Derks NM, Roubos EW, Kozicz T. Presence of estrogen receptor β in urocortin 1-neurons in the mouse non-preganglionic Edinger-Westphal nucleus. General Comparative Endocrinol 2007; 153(1): 228-34.
41. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder. JAMA: J Am Medical Association 2003; 289(23): 3095-105.
42. Kant GJ, Lenox RH, Bunnell BN, et al. Comparison of stress response in male and female rats: pituitary cyclic AMP and plasma prolactin, growth hormone and corticosterone. Psychoneuroendocrinology 1983; 8(4): 421-8.
43. Afifi M. Gender differences in mental health. Singapore Med J 2007; 48(5): 385.
44. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276(4): 293-9.
45. Kudielka BM, Kirschbaum C. Sex differences in HPA axis responses to stress: a review. Biological Psychol 2005; 69(1): 113-32.
46. Kitay JI. Sex differences in adrenal cortical secretion in the rat. Endocrinology 1961; 68(5): 818-24.
47. Goebel M, Stengel A, Wang L, Taché Y. Restraint stress activates nesfatin-1-immunoreactive brain nuclei in rats. Brain Res 2009; 1300: 114-24.
48. Yoshida N, Maejima Y, Sedbazar U, et al. Stressor-responsive central nesfatin-1 activates corticotropin-releasing hormone, noradrenaline and serotonin neurons and evokes hypothalamicpituitary-adrenal axis. Aging (Albany NY) 2010; 2(11): 775-84.
49. Herman JP, Flak J, Jankord R. Chronic stress plasticity in the hypothalamic paraventricular nucleus. Progress Brain Res 2008; 170: 353-64.
50. Sawchenko P, Imaki T, Potter E, et al. The functional neuroanatomy of corticotropin-releasing factor. Corticotropinreleasing factor 1993: 5-29.
51. Knobloch HS, Charlet A, Hoffmann LC, et al. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron 2012; 73(3): 553-66.
52. Young KA, Gobrogge KL, Liu Y, Wang Z. The neurobiology of pair bonding: insights from a socially monogamous rodent. Frontiers Neuroendocrinol 2011; 32(1): 53-69.
53. Caldwell HK, Lee HJ, Macbeth AH, Young III WS. Vasopressin: behavioral roles of an "original" neuropeptide. Progress Neurobiol 2008; 84(1): 1-24.
54. Scott LV, Dinan TG. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci 1998; 62(22): 1985.
55. Aguilera G, Subburaju S, Young S, Chen J. The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Progress Brain Res 2008; 170: 29-39.
56. Stengel A, Goebel-Stengel M, Jawien J, et al. Lipopolysaccharide increases gastric and circulating NUCB2/nesfatin-1 concentrations in rats. Peptides 2011; 32(9): 1942-7.
57. Stengel A, Goebel M, Wang L, Taché Y. Abdominal surgery activates nesfatin-1 immunoreactive brain nuclei in rats. Peptides 2010; 31(2): 263-70.
58. Maejima Y, Sedbazar U, Suyama S, et al. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metabol 2009; 10(5): 355-65.
59. Price C, Hoyda T, Samson W, Ferguson A. Nesfatin-1 Influences the Excitability of Paraventricular Nucleus Neurones. J Neuroendocrinol 2008; 20(2): 245-50.
60. Bishop SJ. Neurocognitive mechanisms of anxiety: an integrative account. Trends Cognitive Sci 2007; 11(7): 307-16.
61. Kent JM, Rauch SL. Neurocircuitry of anxiety disorders. Curr Psychiatry Reports 2003; 5(4): 266-73.
62. Singewald N. Altered brain activity processing in high-anxiety rodents revealed by challenge paradigms and functional mapping. Neurosci Biobehavioral Rev 2007; 31(1): 18-40.
63. Stoppel C, Albrecht A, Pape HC, Stork O. Genes and neurons: molecular insights to fear and anxiety. Genes, Brain Behavior 2006; 5(s2): 34-47.
64. Merali Z, McIntosh J, Kent P, Michaud D, Anisman H. Aversive and appetitive events evoke the release of corticotropin-releasing hormone and bombesin-like peptides at the central nucleus of the amygdala. J Neurosci 1998; 18(12): 4758-66.
65. Merali Z, Cayer C, Kent P, Anisman H. Nesfatin-1 increases anxiety-and fear-related behaviors in the rat. Psychopharmacology 2008; 201(1): 115-23.
66. Gunay H, Tutuncu R, Aydin S, Dag E, Abasli D. Decreased plasma nesfatin-1 levels in patients with generalized anxiety disorder. Psychoneuroendocrinology 2012; 37(12): 1949-53.
67. Stengel A, Goebel M, Yakubov I, et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009; 150(1): 232-8.
68. Zhang AQ, Li XL, Jiang CY, et al. Expression of nesfatin-1/NUCB2 in rodent digestive system. World J Gastroenterology: WJG 2010; 16(14): 1735-41.
69. Pan W, Hsuchou H, Kastin AJ. Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides 2007; 28(11): 2223-8.
70. Price TO, Samson WK, Niehoff ML, Banks WA. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 2007; 28(12): 2372-81.
71. Shimizu H, Oh S, Hashimoto K, et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 2009; 150(2): 662-71.
72. Domschke K, Dannlowski U, Hohoff C, et al. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol 2010; 20(5): 301-9.
73. Caberlotto L, Fuxe K, Overstreet DH, Gerrard P, Hurd YL. Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Molecular Brain Res 1998; 59(1): 58-65.
74. Rotzinger S, Lovejoy DA, Tan LA. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 2010; 31(4): 736-56.
75. Leonard BE. The role of noradrenaline in depression: A review. J Psychopharmacol 1997; 11(4): S39-S47.
76. Kranz G, Kasper S, Lanzenberger R. Reward and the serotonergic system. Neuroscience 2010; 166(4): 1023-35.
77. Itoi K. Ablation of the central noradrenergic neurons for unraveling their roles in stress and anxiety. Annals New York Acad Sci 2008; 1129(1): 47-54.
78. Blume A, Bosch OJ, Miklos S, et al. Oxytocin reduces anxiety via ERK1/2 activation: local effect within the rat hypothalamic paraventricular nucleus. Eur J Neurosci 2008; 27(8): 1947-56.
79. Murgatroyd C, Wigger A, Frank E, et al. Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety. J Neurosci 2004; 24(35): 7762-70.
80. Wigger A, Sánchez MM, Mathys KC, et al. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Neuropsychopharmacology; Neuropsychopharmacol 2004; 29(1): 1-14.
81. Rao TL, Kokare DM, Sarkar S, et al. GABAergic agents prevent alpha-melanocyte stimulating hormone induced anxiety and anorexia in rats. Pharmacol Biochem Behavior 2003; 76(3): 417-23.
82. Ari M, Ozturk OH, Bez Y, Oktar S, Erduran D. High plasma nesfatin-1 level in patients with major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 2011; 35(2): 497-500.
83. Bloem B, Xu L, Morava É, et al. Sex-specific differences in the dynamics of cocaine-and amphetamine-regulated transcript and nesfatin-1 expressions in the midbrain of suicide victims vs. controls. Neuropharmacology 2012; 62(1): 297-303.
84. McLean CP, Anderson ER. Brave men and timid women? A review of the gender differences in fear and anxiety. Clinical Psychol Rev 2009; 29(6): 496-505.
85. Calvez J, Fromentin G, Nadkarni N, et al. Inhibition of food intake induced by acute stress in rats is due to satiation effects. Physiol Behavior 2011; 104(5): 675-83.
86. Stengel A, Goebel-Stengel M, Wang L, et al. Nesfatin-1 (30-59) but not the N-and C-terminal fragments, nesfatin-1 (1-29) and nesfatin-1 (60-82) injected intracerebroventricularly decreases dark phase food intake by increasing inter-meal intervals in mice. Peptides 2012; 35(2): 143-8.